JP2017507160A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507160A5
JP2017507160A5 JP2016555752A JP2016555752A JP2017507160A5 JP 2017507160 A5 JP2017507160 A5 JP 2017507160A5 JP 2016555752 A JP2016555752 A JP 2016555752A JP 2016555752 A JP2016555752 A JP 2016555752A JP 2017507160 A5 JP2017507160 A5 JP 2017507160A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
amino
aryl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555752A
Other languages
English (en)
Japanese (ja)
Other versions
JP6574435B2 (ja
JP2017507160A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/019535 external-priority patent/WO2015134998A1/en
Publication of JP2017507160A publication Critical patent/JP2017507160A/ja
Publication of JP2017507160A5 publication Critical patent/JP2017507160A5/ja
Priority to JP2019149385A priority Critical patent/JP6915003B2/ja
Application granted granted Critical
Publication of JP6574435B2 publication Critical patent/JP6574435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555752A 2014-03-07 2015-03-09 ヒト血漿カリクレイン阻害剤 Active JP6574435B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019149385A JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461949808P 2014-03-07 2014-03-07
US61/949,808 2014-03-07
US201461981515P 2014-04-18 2014-04-18
US61/981,515 2014-04-18
PCT/US2015/019535 WO2015134998A1 (en) 2014-03-07 2015-03-09 Human plasma kallikrein inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019149385A Division JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤

Publications (3)

Publication Number Publication Date
JP2017507160A JP2017507160A (ja) 2017-03-16
JP2017507160A5 true JP2017507160A5 (enExample) 2018-08-09
JP6574435B2 JP6574435B2 (ja) 2019-09-11

Family

ID=54055948

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016555752A Active JP6574435B2 (ja) 2014-03-07 2015-03-09 ヒト血漿カリクレイン阻害剤
JP2019149385A Active JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤
JP2021116716A Pending JP2021169499A (ja) 2014-03-07 2021-07-14 ヒト血漿カリクレイン阻害剤
JP2023189564A Pending JP2023181543A (ja) 2014-03-07 2023-11-06 ヒト血漿カリクレイン阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019149385A Active JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤
JP2021116716A Pending JP2021169499A (ja) 2014-03-07 2021-07-14 ヒト血漿カリクレイン阻害剤
JP2023189564A Pending JP2023181543A (ja) 2014-03-07 2023-11-06 ヒト血漿カリクレイン阻害剤

Country Status (33)

Country Link
US (14) US10125102B2 (enExample)
EP (4) EP4180424B1 (enExample)
JP (4) JP6574435B2 (enExample)
KR (2) KR102510427B1 (enExample)
CN (2) CN106257976B (enExample)
AU (3) AU2015226855C1 (enExample)
BR (1) BR112016020199A8 (enExample)
CA (2) CA2941380C (enExample)
CY (2) CY1123810T1 (enExample)
DK (2) DK3113772T3 (enExample)
EA (1) EA036251B1 (enExample)
ES (3) ES2836373T3 (enExample)
FR (1) FR21C1048I2 (enExample)
HR (2) HRP20201916T1 (enExample)
HU (3) HUE052668T2 (enExample)
IL (2) IL280785B2 (enExample)
LT (3) LT3828173T (enExample)
LU (1) LUC00233I2 (enExample)
MA (1) MA53399B1 (enExample)
MX (2) MX377845B (enExample)
MY (1) MY199131A (enExample)
NL (1) NL301142I2 (enExample)
NO (1) NO2022046I1 (enExample)
NZ (2) NZ724250A (enExample)
PH (1) PH12016501750B1 (enExample)
PL (2) PL3113772T3 (enExample)
PT (2) PT3828173T (enExample)
RS (2) RS63763B1 (enExample)
SG (2) SG11201607267SA (enExample)
SI (1) SI3113772T1 (enExample)
SM (2) SMT202100031T1 (enExample)
WO (1) WO2015134998A1 (enExample)
ZA (1) ZA201606320B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
TWI859674B (zh) 2014-01-31 2024-10-21 美商必治妥美雅史谷比公司 作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物
NO2760821T3 (enExample) 2014-01-31 2018-03-10
EP4180424B1 (en) 2014-03-07 2025-06-25 BioCryst Pharmaceuticals, Inc. Substituted pyrazoles as human plasma kallikrein inhibitors
US10081623B2 (en) 2014-09-04 2018-09-25 Bristol-Myers Squibb Company Diamide macrocycles that are FXIa inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
RS65443B1 (sr) * 2015-10-01 2024-05-31 Biocryst Pharm Inc Inhibitori kalikreina humane plazme
IL263235B (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazoles as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
JP7078722B2 (ja) 2017-11-29 2022-05-31 カルビスタ・ファーマシューティカルズ・リミテッド 血漿カリクレイン阻害剤を含む剤形
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
AR116951A1 (es) * 2018-11-02 2021-06-30 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP7668227B2 (ja) * 2019-04-08 2025-04-24 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 血漿カリクレイン阻害剤および眼障害におけるその使用方法
WO2021025969A1 (en) 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
MX2022001608A (es) * 2019-08-06 2022-03-11 Biocryst Pharm Inc Sintesis de un inhibidor de calicreina plasmatica a escala de proceso.
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2021032935A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
EP4107166A4 (en) 2020-02-20 2024-06-26 Achillion Pharmaceuticals, Inc. HETEROARYL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D-MEDIATED DISORDERS
EP4116299A4 (en) * 2020-03-04 2024-03-27 Medshine Discovery Inc. HETEROCYCLIC COMPOUND
JP7776453B2 (ja) * 2020-06-16 2025-11-26 メルク・シャープ・アンド・ドーム・エルエルシー 血漿カリクレイン阻害剤
WO2022010828A1 (en) * 2020-07-10 2022-01-13 Merck Sharp & Dohme Corp. Plasma kallikrein inhibitors
WO2022060842A1 (en) * 2020-09-15 2022-03-24 The Trustees Of Columbia University In The City Of New York Systems and methods for predicting graft dysfunction with exosome proteins
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法
WO2025122555A1 (en) * 2023-12-05 2025-06-12 Valo Health, Inc. S1p 1 receptor agonists and uses thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
DE3633840A1 (de) 1986-10-04 1988-04-14 Hoechst Ag Phenylpyrazolcarbonsaeurederivate, ihre herstellung und verwendung als pflanzenwachstumsregulatoren und safener
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
HUP0000735A3 (en) * 1996-12-23 2002-03-28 Bristol Myers Squibb Pharma Co Nitrogen containing heteroaromatics as factor xa inhibitors
JP2002507968A (ja) * 1997-06-19 2002-03-12 デュポン ファーマシューティカルズ カンパニー 中性のＰ１特異性基を有するＸａ因子阻害剤
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US6271237B1 (en) * 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
BR9813835A (pt) * 1997-12-22 2000-10-10 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
JP3419395B2 (ja) * 1999-02-10 2003-06-23 三菱ウェルファーマ株式会社 アミド化合物およびその医薬としての用途
DE60003025T2 (de) 1999-04-02 2004-03-18 Bristol-Myers Squibb Pharma Co. Arylsulfonyle als faktor xa inhibitoren
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
IL153707A0 (en) 2000-06-27 2003-07-06 S A L V A T Lab Sa Carbamates derived from arylalkylamines
HUP0500133A2 (hu) 2000-09-22 2005-04-28 Bristol-Myers Squibb Pharma Company Hatékony eljárás Xa faktor inhibitorának előállítására
CA2442557C (en) 2001-04-12 2008-12-23 F. Hoffmann-La Roche Ag Dihydro-benzo¬b|¬1,4|diazepin-2-one derivatives as mglur2 antagonists ii
ATE469892T1 (de) * 2001-08-13 2010-06-15 Du Pont Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
TWI312274B (en) 2001-08-13 2009-07-21 Du Pont Method for controlling particular insect pests by applying anthranilamide compounds
JP2005504084A (ja) * 2001-09-21 2005-02-10 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺虫性ジアミド
TWI283164B (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
AU2003245464A1 (en) * 2002-06-13 2003-12-31 E.I. Du Pont De Nemours And Company Pyrazole and pyrrole carboxamide insecticides
DE10229070A1 (de) * 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
AU2004218260A1 (en) 2003-01-28 2004-09-16 Aventis Pharma S.A. N-aryl heteroaromatic products, compositions containing same and use thereof
JP4895811B2 (ja) 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
WO2005094805A1 (ja) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
WO2005118552A2 (en) 2004-04-13 2005-12-15 E.I. Dupont De Nemours And Company Anthranilamide insecticides
US20050272784A1 (en) 2004-05-07 2005-12-08 Xiaobing Li Inhibitors of bacterial Type III protein secretion systems
US20060069270A1 (en) 2004-09-27 2006-03-30 Rafael Shapiro Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1812421B9 (en) 2004-11-18 2013-09-25 E.I. Du Pont De Nemours And Company Anthranilamide insecticides
EP1820795A4 (en) * 2004-12-07 2010-10-20 Toyama Chemical Co Ltd NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
GB0516703D0 (en) 2005-08-15 2005-09-21 Syngenta Participations Ag Novel insecticides
PL1937664T3 (pl) 2005-10-14 2011-11-30 Sumitomo Chemical Co Związki hydrazydowe i ich zastosowanie jako pestycydy
JP5186751B2 (ja) * 2005-10-14 2013-04-24 住友化学株式会社 ヒドラジド化合物およびその有害生物防除用途
PE20070795A1 (es) 2005-10-28 2007-08-24 Lilly Co Eli Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
DK1988777T3 (da) 2006-02-09 2012-01-16 Athersys Inc Pyrazoler til behandling af fedme og andre cns-lidelser
AU2007251614B2 (en) * 2006-05-16 2013-01-17 Boehringer Ingelheim International Gmbh Substituted prolinamides, production thereof and their use as drugs
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
AU2007317349B2 (en) * 2006-11-03 2011-10-20 Irm Llc Compounds and compositions as protein kinase inhibitors
JP5399262B2 (ja) * 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
WO2008134969A1 (fr) 2007-04-30 2008-11-13 Sinochem Corporation Composés benzamides et leurs applications
CN101298451B (zh) 2007-04-30 2013-01-30 中国中化股份有限公司 苯甲酰胺类化合物及其应用
EP2484676B1 (de) 2008-12-18 2015-01-21 Bayer CropScience AG Tetrazolsubstituierte Anthranilsäureamide als Pestizide
US8980892B2 (en) 2009-03-26 2015-03-17 Syngenta Crop Protection Llc Insecticidal compounds
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
CA2783801A1 (en) 2009-12-18 2011-06-23 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
JP5760010B2 (ja) 2010-02-01 2015-08-05 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
WO2011118818A1 (ja) 2010-03-26 2011-09-29 味の素株式会社 アミジノアニリン誘導体
CN102285963B (zh) 2010-06-21 2014-04-09 中国中化股份有限公司 3-甲氧基吡唑酰胺类化合物及其应用
BR112013003815A2 (pt) 2010-08-20 2019-09-24 Gruenenthal Chemie derivados de carboxamida cílicos substituódos e derivados de ureia como ligantes do receptor vaniloide
MX2013005008A (es) 2010-11-10 2013-08-01 Gruenenthal Gmbh Derivados de carboxamida y urea heteroaromaticos sustituidos como ligandos del receptor vanilloide.
US9284298B2 (en) 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
WO2012142308A1 (en) * 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2013036232A2 (en) 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
HK1202117A1 (en) 2011-11-09 2015-09-18 Grünenthal GmbH Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an so2-containing group as vanilloid receptor ligands
CN103467380B (zh) 2013-09-29 2015-06-24 南开大学 一类取代苯基吡唑酰胺衍生物及其制备方法和应用
EP4180424B1 (en) 2014-03-07 2025-06-25 BioCryst Pharmaceuticals, Inc. Substituted pyrazoles as human plasma kallikrein inhibitors
AR116951A1 (es) 2018-11-02 2021-06-30 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
MX2022001608A (es) 2019-08-06 2022-03-11 Biocryst Pharm Inc Sintesis de un inhibidor de calicreina plasmatica a escala de proceso.

Similar Documents

Publication Publication Date Title
JP2017507160A5 (enExample)
JP2021169499A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CN111848615B (zh) 吡啶酮衍生物及包含其的抗流感病毒药物组合物
JP2018526367A5 (enExample)
JP2018535963A5 (enExample)
JP2018536648A5 (enExample)
JP2014515349A5 (enExample)
HRP20221373T1 (hr) Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
JP2016515560A5 (enExample)
KR102519536B1 (ko) 트리시클릭 회전장애이성질체 화합물
JP2015531773A5 (enExample)
RU2019100164A (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
JP2017512833A5 (enExample)
JP6635562B2 (ja) アルキニルピリジンプロリルヒドロキシラーゼ阻害剤、及びその製造法及び医薬用途
JP2017137291A5 (enExample)
JP2018529721A5 (enExample)
JP2015163632A5 (enExample)
JP2006528621A5 (enExample)
JP2018531218A5 (enExample)
JP2016528273A5 (enExample)
HRP20240557T1 (hr) Inhibitori kalikreina ljudske plazme
JP2018529690A5 (enExample)
BR122017005939A2 (pt) processo para a fabricação de derivados de sulfamida pirimidina
JP2017538767A5 (enExample)